Tysabri risk causing headache for companies.
Sheridan
Cormac
C
D016907:Adverse Drug Reaction Reporting Systems / Q000941:ethics / Q000331:legislation & jurisprudence / Q000592:standards; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000150:complications; D004345:Drug Industry / Q000941:ethics* / Q000458:organization & administration*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000453:epidemiology; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy; D000069442:Natalizumab; D018570:Risk Assessment / Q000941:ethics / Q000379:methods / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000592:standards
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab